Therapeutic uses of actin-binding compounds
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsThomas P. Stossel, Stuart E. Lind, Paul A. Janmey
Life of this patent
Estimating the term…
Abstract
A method for decreasing the concentration of free actin in the plasma of an animal is described which comprises the administration of native and modified actin-binding proteins, and especially the administration of native and modified actin-binding regions of gelsolin. Diagnostic methods for identifying animals in need of such treatment are also described.
Claims7
A method for inhibiting secondary tissue injury resulting from the accumulation of excess, extracellular free actin in a subject comprising the step of administering to the subject an efficacious level of at least one actin-binding compound.
A method for decreasing the concentration of extracellular free actin in the blood or extracellular fluids of a subject, comprising the step of administering to said subject an amount of at least one actin-binding compound which is sufficient to bind said extracellular free actin.
A method for blocking the inhibition of fibrinolysis by excess, extracellular free actin in a subject, comprising the step of administering to the subject an efficacious level of at least one actin-binding compound.
A pharmaceutical composition for use in inhibiting secondary tissue injury in a subject resulting from the accumulation of excess extracellular free actin comprising:
- (1) at least one actin-binding compound or a biologically-active fragment thereof, wherein such compound or said fragment is substantially free of natural contaminants;
- and,
- (2) a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.